☆ 4.7 Article

Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy

JOURNAL OF NEUROINFLAMMATION (2023)

Related references

Note: Only part of the references are listed.
Review Microbiology

Epstein-Barr virus and multiple sclerosis

Samantha S. Soldan et al.

Summary: EBV plays a significant role in the development of multiple sclerosis (MS) through the reprogramming of infected B lymphocytes and the chronic presentation of viral antigens. Understanding how EBV contributes to MS may also provide insights into the relationship between EBV and cancer.

NATURE REVIEWS MICROBIOLOGY (2023)

Add to Collection
Article Clinical Neurology

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets A MAGNIFY-MS Substudy

Heinz Wiendl et al.

Summary: Cladribine tablets cause a reduction in lymphocytes, with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after the first course of cladribine tablets in patients with highly active relapsing multiple sclerosis (MS).

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Add to Collection
Article Immunology

Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients

Christoph Ruschil et al.

Summary: This study investigated the effects of cladribine treatment on B cell repertoire in multiple sclerosis patients. The results showed that cladribine therapy decreased memory B cell numbers and increased naive B cell numbers. However, it had minimal impact on the composition and diversity of immunoglobulins. The study also found that a proportion of B cell clones were maintained during treatment.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Review Microbiology

Epstein-Barr virus and multiple sclerosis

Samantha S. Soldan et al.

Summary: This review article examines the evidence for EBV as a causal agent of MS and discusses how various risk factors can affect EBV infection and immune control. The article focuses on the reprogramming of latently infected B lymphocytes by EBV and the chronic presentation of viral antigens as a potential mechanism for MS development. The potential for therapies targeting EBV to treat MS is also discussed.

NATURE REVIEWS MICROBIOLOGY (2023)

Add to Collection
Review Pharmacology & Pharmacy

Ocrelizumab: A Review in Multiple Sclerosis

Yvette N. Lamb

Summary: Multiple sclerosis is a chronic neurodegenerative disease where Ocrelizumab, a monoclonal antibody, has been proven to be a highly effective and convenient treatment option for patients with relapsing forms of MS and primary progressive MS. It reduces relapse rates, delays disability progression, and has shown no new safety signals with long-term use.

DRUGS (2022)

Add to Collection
Editorial Material Pharmacology & Pharmacy

Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis

[Anonymous]

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Coordination of transcription and processing of tRNA

Nayef Jarrous et al.

Summary: The article discusses the coordination of transcription and processing of RNA in eukaryotes as a basic principle of gene expression regulation. It presents a model of high molecular weight initiation complexes of human RNA polymerase III on tRNA genes, highlighting their role in co-transcriptional processing of tRNA precursors to mature forms.

FEBS JOURNAL (2022)

Add to Collection
Article Clinical Neurology

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

Nicola De Stefano et al.

Summary: The study demonstrates that oral treatment with cladribine tablets significantly reduces the relapse rate and severity in patients with multiple sclerosis, with sustained efficacy even without further treatment.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection
Article Cell Biology

Peripheral B-cell dysregulation is associated with relapse after long-term quiescence in patients with multiple sclerosis

Felix Marsh-Wakefield et al.

Summary: B cells play a major role in multiple sclerosis (MS), and alemtuzumab therapy can restore B cell damage, which is of great significance in preventing the progression of the disease.

IMMUNOLOGY AND CELL BIOLOGY (2022)

Add to Collection
Article Clinical Neurology

Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study

Leoni Rolfes et al.

Summary: Cladribine treatment led to selective alterations in immune cell populations, with the most marked reduction seen in B cells. Despite significant reduction in B cells, immunoglobulin levels remained unaffected. Herpes infections were more likely to occur during lymphopenia.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection
Article Medicine, General & Internal

Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis

Michael Hecker et al.

Summary: This study found that MS-associated SNPs can affect the expression of mature miRNAs and provided insights into the dysregulation of miRNAs in MS. Further studies on the maturation and function of miRNAs in different cell types and tissues may help to gain a more detailed functional understanding of the genetic basis of MS.

EBIOMEDICINE (2022)

Add to Collection
Review Cell Biology

Prohibitins: A Key Link between Mitochondria and Nervous System Diseases

Tianlin Jiang et al.

Summary: Prohibitins (PHBs) are conserved proteins in eukaryotic cells and play crucial roles in various cellular functions. Recent studies have shown that PHBs are important in preventing apoptosis, inflammation, mitochondrial dysfunction, and autophagy in neurological disorders.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2022)

Add to Collection
Article Cell Biology

The Mitochondrial Pathway of Apoptosis Part II: The BCL-2 Protein Family

Douglas R. Green

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2022)

Add to Collection
Article Immunology

Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing

Elena Putscher et al.

Summary: This study found that genetic variants from MS risk loci affect pre-mRNA splicing. These findings substantiate the role of alternative splicing events in the genetics of MS. Further research on how disease-causing genetic variants modify the interactions between splicing regulatory sequence elements and RNA-binding proteins can help deepen our understanding of the genetic susceptibility to MS.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Immunology

A close-up on the expanding landscape of CD21-/low B cells in humans

Inger Gjertsson et al.

Summary: This review focuses on memory B cells (MBCs) that lack or express low levels of CD21 (CD21-/low MBCs). These cells are expanded in various diseases and with age. They can be classified into different subsets based on markers and have different names. It is currently unclear whether these cells are equivalent in different conditions.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)

Add to Collection
Article Biotechnology & Applied Microbiology

Dissection of multiple sclerosis genetics identifies B and CD4+T cells as driver cell subsets

Michael H. Guo et al.

Summary: This study utilizes chromatin accessibility data to identify cell type-specific enrichments of multiple sclerosis (MS) genetic signals, finding that CD4 T cells and B cells independently drive the genetic signals of MS. The study also identifies driver subsets and proposes potential causal genes through fine-mapping and chromatin interactions.

GENOME BIOLOGY (2022)

Add to Collection
Article Clinical Neurology

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity

Tobias Ruck et al.

Summary: Ruck et al. investigate the immunological basis of secondary autoimmunity after alemtuzumab and find that the dynamics of clonal T- and B-cell expansions are associated with the development of autoimmunity. They suggest that T-cell receptor repertoire analyses at baseline may help predict secondary autoimmunity and guide clinical decision-making.

BRAIN (2022)

Add to Collection
Article Multidisciplinary Sciences

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis

Kjetil Bjornevik et al.

Summary: This study suggests that multiple sclerosis may be caused by Epstein-Barr virus, with no direct association with other viral infections. These findings provide clues to the primary cause of MS.

SCIENCE (2022)

Add to Collection
Review Clinical Neurology

Role of B Cells in Multiple Sclerosis and Related Disorders

Giancarlo Comi et al.

Summary: Selective B-cell depletion in patients with relapsing multiple sclerosis and primary progressive MS has led to a conceptual shift in understanding the pathogenesis of MS, highlighting the essential role of B cells in both inflammatory and neurodegenerative components of the disease.

ANNALS OF NEUROLOGY (2021)

Add to Collection
Article Immunology

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

Andrea Cossarizza et al.

Summary: The third edition of Flow Cytometry Guidelines provides comprehensive information on phenotypes and functional assays of major human and murine immune cell subsets, as well as clinical sample analysis and applications in various diseases. It also includes expert tips, tricks, and pitfalls to avoid, making it an essential handbook for researchers.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Add to Collection
Article Clinical Neurology

Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care

Kris Oliver Jalusic et al.

Summary: The majority of multiple sclerosis (MS) patients treated in routine care would not have met the eligibility criteria for phase III clinical trials, with relapse being the most common criterion not fulfilled. The study suggests that broader inclusion criteria in clinical trials could improve generalizability of the results.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection
Review Medicine, General & Internal

Diagnosis and Treatment of Multiple Sclerosis A Review

Marisa P. McGinley et al.

Summary: Multiple sclerosis is a neurodegenerative disease that affects the central nervous system, leading to physical disability, cognitive impairment and decreased quality of life. Current disease-modifying therapies can reduce relapse rates by 29% to 68% compared to placebo or active comparators.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection
Article Clinical Neurology

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab

Steffen Pfeuffer et al.

Summary: In a retrospective evaluation of a prospective dual-centre alemtuzumab cohort of 170 patients, it was found that patients previously treated with fingolimod had suboptimal disease control and increased risk of secondary autoimmunity following alemtuzumab treatment. These findings can guide the improvement of MS therapeutic management.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Add to Collection
Article Health Care Sciences & Services

Efficacy classification of modern therapies in multiple sclerosis

Imtiaz A. Samjoo et al.

Summary: According to the ABN guidelines, cladribine and ofatumumab are classified as high efficacy treatments, while ocrelizumab and ozanimod (1.0 mg) are classified as moderate or high efficacy depending on the approach used.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Add to Collection
Article Genetics & Heredity

Knockdown of RIPK2 Inhibits Proliferation and Migration, and Induces Apoptosis via the NF-κB Signaling Pathway in Gastric Cancer

Qian Yang et al.

Summary: This study revealed that RIPK2 is overexpressed in gastric cancer and downregulating RIPK2 in GC cells can suppress cell growth, migration, and induce apoptosis through the NF-κB signaling pathway. RIPK2 functions as a potential oncogene in modulating GC cell proliferation, migration, and apoptosis. These findings suggest that RIPK2 could serve as a candidate biomarker, diagnostic tool, and therapeutic target for GC.

FRONTIERS IN GENETICS (2021)

Add to Collection
Article Cell Biology

Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis

Tobias Moser et al.

Summary: In this study, the impact of CLAD tablets on immune cell surface molecules in people with MS was investigated, showing significant differences in expression and density of certain molecules compared to healthy controls, particularly in B cells, which may play a key role in the pathogenesis of MS.

CELLS (2021)

Add to Collection
Article Immunology

CD1a selectively captures endogenous cellular lipids that broadly block T cell response

Rachel N. Cotton et al.

Summary: The study indicates that cellular CD1a protein preferentially captures specific endogenous lipids that block its binding to T cell receptors, suggesting that this inhibitory effect may play a key role in the intrinsic autoreactivity and negative regulation of the CD1a system.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis

Michael Hecker et al.

Summary: Telomeres, protective structures at the ends of chromosomes, are linked to biological aging and disorders like MS. Genetic, environmental, and lifestyle factors influence telomere length and MS susceptibility, with early-life factors like obesity, inactivity, smoking, and vitamin D deficiency associated with reduced TL and higher MS risk. Further research is needed to understand the role of telomeres in disease processes and potential interventions in MS.

BIOMOLECULES (2021)

Add to Collection
Review Immunology

New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4

Anna Erdei et al.

Summary: Complement is known to regulate antibody responses and additional B cell functions such as cytokine production and antigen presentation. These activities are mediated by receptors interacting with activation fragments of C3, attached to antigens and immune complexes. This review focuses on human B lymphocytes and highlights important differences between human and mouse systems.

IMMUNOLOGY LETTERS (2021)

Add to Collection
Review Clinical Neurology

Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances

Amit Bar-Or et al.

Summary: The pathogenesis of multiple sclerosis is being redefined by new insights from basic and translational studies, indicating involvement of various cell types and subsets in the inflammatory responses. Imbalanced interactions between T cells, myeloid cells, B cells, and their subpopulations play a crucial role in relapsing multiple sclerosis, with patient-specific contributors to these imbalances. Single-cell immune cell profiling techniques reveal functional heterogeneity and plasticity that could impact disease progression and treatment response. Clinical trials with different agents have helped to elucidate disease mechanisms, clarify immune therapy modes of action, and set the stage for new therapeutic strategies.

LANCET NEUROLOGY (2021)

Add to Collection
Review Clinical Neurology

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies

Maria T. Cencioni et al.

Summary: This Review discusses the roles of B cells in multiple sclerosis, highlighting the involvement of B cells in disease pathogenesis and the potential mechanisms underlying the abnormalities in B cell function in MS.

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection
Article Clinical Neurology

Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis

Alexander Cuculiza Henriksen et al.

Summary: Natalizumab treatment increases B cell frequencies and reduces IgG concentrations, affecting plasmablast development. Plasmablast numbers remain stable, with high CD49d expression, and are undetectable in CSF with treatment.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection
Review Clinical Neurology

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Heinz Wiendl et al.

Summary: The article discusses multiple sclerosis as a complex autoimmune disease of the central nervous system, highlighting the recent approval of disease-modifying therapies and increased understanding of disease mechanisms that have significantly altered the prognosis and course of the disease. The update from the Multiple Sclerosis Therapy Consensus Group focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021, based on current scientific evidence and applicable to wide parts of Europe, particularly German-speaking countries.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection
Article Clinical Neurology

T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients

Laura Ghezzi et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection
Article Clinical Neurology

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

Heinz Wiendl et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection
Review Immunology

Immunological consequences of immune reconstitution therapy in multiple sclerosis: A systematic review

Johann Sellner et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Functional diversity of small nucleolar RNAs

Tomaz Bratkovic et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection
Article Physiology

Knockdown of SLC38 Transporter Ortholog-CG13743 Reveals a Metabolic Relevance in Drosophila

Tanya Aggarwal et al.

FRONTIERS IN PHYSIOLOGY (2020)

Add to Collection
Article Clinical Neurology

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

Sargis Abrahamyan et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Add to Collection
Review Medicine, General & Internal

Treatment of Multiple Sclerosis: A Review

Stephen L. Hauser et al.

AMERICAN JOURNAL OF MEDICINE (2020)

Add to Collection
Article Immunology

Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe

A. Oras et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

Add to Collection
Article Clinical Neurology

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Tjalf Ziemssen et al.

CNS DRUGS (2020)

Add to Collection
Review Neurosciences

Protocadherins at the Crossroad of Signaling Pathways

Anna Pancho et al.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)

Add to Collection
Article Immunology

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

Wendy Gilmore et al.

JOURNAL OF NEUROINFLAMMATION (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Single-cell multiomics: technologies and data analysis methods

Jeongwoo Lee et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

Add to Collection
Article Clinical Neurology

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Tobias Moser et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

Add to Collection
Review Oncology

Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor

Rahul Mal et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Article Clinical Neurology

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Clare Walton et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection
Article Cell Biology

RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types

Gianni Monaco et al.

CELL REPORTS (2019)

Add to Collection
Article Biology

The homophilic receptor PTPRK selectively dephosphorylates multiple junctional regulators to promote cell-cell adhesion

Gareth W. Fearnley et al.

ELIFE (2019)

Add to Collection
Review Clinical Neurology

Potential mechanisms of action related to the efficacy and safety of cladribine

David Baker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection
Review Immunology

Immunological Aspects of Approved MS Therapeutics

Paulus S. Rommer et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Article Immunology

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients

Jan W. Traub et al.

JOURNAL OF NEUROINFLAMMATION (2019)

Add to Collection
Article Clinical Neurology

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis

Jan D. Lünemann et al.

Nature Reviews Neurology (2019)

Add to Collection
Review Immunology

The Complex Association of FcγRIIb With Autoimmune Susceptibility

J. Sjef Verbeek et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Review Clinical Neurology

Pulsed immune reconstitution therapy in multiple sclerosis

Per Soelberg Sorensen et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)

Add to Collection
Article Cell Biology

Structure of the human activated spliceosome in three conformational states

Xiaofeng Zhang et al.

CELL RESEARCH (2018)

Add to Collection
Article Clinical Neurology

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

Bryan Ceronie et al.

JOURNAL OF NEUROLOGY (2018)

Add to Collection
Article Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Alan J. Thompson et al.

LANCET NEUROLOGY (2018)

Add to Collection
Article Biochemistry & Molecular Biology

GeneMANIA update 2018

Max Franz et al.

NUCLEIC ACIDS RESEARCH (2018)

Add to Collection
Article Medicine, Research & Experimental

Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells

Mingshi Zhang et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2018)

Add to Collection
Review Immunology

Tuning the Cytokine Responses: An Update on interleukin (IL)-4 and IL-13 Receptor Complexes

Ilkka S. Junttila

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

Ivan Jelcic et al.

CELL (2018)

Add to Collection
Article Medicine, General & Internal

Multiple sclerosis

Massimo Filippi et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Add to Collection
Article Clinical Neurology

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

Thomas Berger et al.

CNS DRUGS (2017)

Add to Collection
Review Clinical Neurology

Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis

Tomas Olsson et al.

NATURE REVIEWS NEUROLOGY (2017)

Add to Collection
Article Cell Biology

Targeted CRISPR disruption reveals a role for RNase MRP RNA in human preribosomal RNA processing

Katherine C. Goldfarbi et al.

GENES & DEVELOPMENT (2017)

Add to Collection
Editorial Material Clinical Neurology

Cladribine - an old newcomer for pulsed immune reconstitution in MS

Heinz Wiendl

NATURE REVIEWS NEUROLOGY (2017)

Add to Collection
Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection
Article Clinical Neurology

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

David Baker et al.

JAMA NEUROLOGY (2017)

Add to Collection
Review Medicine, General & Internal

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

David Baker et al.

EBIOMEDICINE (2017)

Add to Collection
Article Biotechnology & Applied Microbiology

RNA sequencing and transcriptome arrays analyses show opposing results for alternative splicing in patient derived samples

Petr V. Nazarov et al.

BMC GENOMICS (2017)

Add to Collection
Article Clinical Neurology

Both cladribine and alemtuzumab may effect MS via B-cell depletion

David Baker et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection
Review Toxicology

IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis

Ghasem Ghalamfarsa et al.

JOURNAL OF IMMUNOTOXICOLOGY (2016)

Add to Collection
Article Biochemical Research Methods

flowAI: automatic and interactive anomaly discerning tools for flow cytometry data

Gianni Monaco et al.

BIOINFORMATICS (2016)

Add to Collection
Article Immunology

B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses

Judith Fraussen et al.

CLINICAL IMMUNOLOGY (2016)

Add to Collection
Article Biochemical Research Methods

Age and gender leucocytes variances and references values generated using the standardized ONE-Study protocol

Anders H. Kverneland et al.

CYTOMETRY PART A (2016)

Add to Collection
Review Clinical Neurology

Disease-modifying therapies and infectious risks in multiple sclerosis

Alexander Winkelmann et al.

NATURE REVIEWS NEUROLOGY (2016)

Add to Collection
Review Biochemistry & Molecular Biology

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

Tobias Ruck et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)

Add to Collection
Article Computer Science, Interdisciplinary Applications

Fitting Linear Mixed-Effects Models Using lme4

Douglas Bates et al.

JOURNAL OF STATISTICAL SOFTWARE (2015)

Add to Collection
Review Immunology

CD21-/low B cells: A Snapshot of a Unique B Cell Subset in Health and Disease

K. Thorarinsdottir et al.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2015)

Add to Collection
Article Multidisciplinary Sciences

Roquin binds microRNA-146a and Argonaute2 to regulate microRNA homeostasis

Monika Srivastava et al.

NATURE COMMUNICATIONS (2015)

Add to Collection
Review Biochemistry & Molecular Biology

The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer

Martin W. Berchtold et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)

Add to Collection
Article Biochemistry & Molecular Biology

The ROQ domain of Roquin recognizes mRNA constitutive-decay element and double-stranded RNA

Dazhi Tan et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)

Add to Collection
Article Clinical Neurology

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

Onajite Kousin-Ezewu et al.

NEUROLOGY (2014)

Add to Collection
Review Clinical Neurology

Defining the clinical course of multiple sclerosis The 2013 revisions

Fred D. Lublin et al.

NEUROLOGY (2014)

Add to Collection
Review Physiology

The SLC38 family of sodium-amino acid co-transporters

Stefan Broer

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2014)

Add to Collection
Review Cell Biology

The Molecular Basis of IL-10 Function: from Receptor Structure to the Onset of Signaling

Mark R. Walter

INTERLEUKIN-10 IN HEALTH AND DISEASE (2014)

Add to Collection
Article Immunology

Prohibitins and the Cytoplasmic Domain of CD86 Cooperate To Mediate CD86 Signaling in B Lymphocytes

Christopher R. Lucas et al.

JOURNAL OF IMMUNOLOGY (2013)

Add to Collection
Article Immunology

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis

Raquel Planas et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2012)

Add to Collection
Article Medicine, General & Internal

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair J. Coles et al.

LANCET (2012)

Add to Collection
Article Multidisciplinary Sciences

CD80 and CD86 Differentially Regulate Mechanical Interactions of T-Cells with Antigen-Presenting Dendritic Cells and B-Cells

Tong Seng Lim et al.

PLOS ONE (2012)

Add to Collection
Article Multidisciplinary Sciences

Human transcriptome array for high-throughput clinical studies

Weihong Xu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Add to Collection
Article Virology

Identification of a sub-population of B cells that proliferates after infection with Epstein-Barr virus

Cynthia Megyola et al.

VIROLOGY JOURNAL (2011)

Add to Collection
Article Immunology

Reference values for B cell subpopulations from infancy to adulthood

H. Morbach et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)

Add to Collection
Article Immunology

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

Sara A. J. Thompson et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2010)

Add to Collection
Article Medicine, General & Internal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Gavin Giovannoni et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection
Article Cell Biology

Bcl-2-regulated cell death signalling in the prevention of autoimmunity

D Tischner et al.

Cell Death & Disease (2010)

Add to Collection
Article Medicine, Research & Experimental

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

Joanne L. Jones et al.

JOURNAL OF CLINICAL INVESTIGATION (2009)

Add to Collection
Article Immunology

The Bcl-2 Family Antagonist ABT-737 Significantly Inhibits Multiple Animal Models of Autoimmunity

Philip D. Bardwell et al.

JOURNAL OF IMMUNOLOGY (2009)

Add to Collection
Article Biochemistry & Molecular Biology

The PDZ-LIM protein CLP36 is required for actin stress fiber formation and focal adhesion assembly in BeWo cells

Naoaki Tamura et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)

Add to Collection
Article Immunology

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis

Martin Duddy et al.

JOURNAL OF IMMUNOLOGY (2007)

Add to Collection
Article Biochemical Research Methods

Using GOstats to test gene lists for GO term association

S. Falcon et al.

BIOINFORMATICS (2007)

Add to Collection
Review Cell Biology

The prohibitins: emerging roles in diverse functions

Suresh Mishra et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2006)

Add to Collection
Article Biochemistry & Molecular Biology

Cytoscape: A software environment for integrated models of biomolecular interaction networks

P Shannon et al.

GENOME RESEARCH (2003)

Add to Collection
Article Clinical Neurology

Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase

H Ochi et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2002)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.